Display options
Cite
Schoofs G, Monica TJ, Ayala J, et al. A high-yielding serum-free, suspension cell culture process to manufacture recombinant adenoviral vectors for gene therapy. Cytotechnology. 1998;28(1):81-9doi: 10.1023/A:1008021428969.
Schoofs, G., Monica, T. J., Ayala, J., Horwitz, J., Montgomery, T., Roth, G., & Castillo, F. J. (1998). A high-yielding serum-free, suspension cell culture process to manufacture recombinant adenoviral vectors for gene therapy. Cytotechnology, 28(1), 81-9. https://doi.org/10.1023/A:1008021428969
Schoofs, G, et al. "A high-yielding serum-free, suspension cell culture process to manufacture recombinant adenoviral vectors for gene therapy." Cytotechnology vol. 28,1 (1998): 81-9. doi: https://doi.org/10.1023/A:1008021428969
Schoofs G, Monica TJ, Ayala J, Horwitz J, Montgomery T, Roth G, Castillo FJ. A high-yielding serum-free, suspension cell culture process to manufacture recombinant adenoviral vectors for gene therapy. Cytotechnology. 1998 Nov;28(1):81-9. doi: 10.1023/A:1008021428969. PMID: 19003410; PMCID: PMC3449833.
Copy Download .nbib Format: NLM
Share it on

Cytotechnology. 1998 Nov;28(1):81-9. doi: 10.1023/A:1008021428969.

A high-yielding serum-free, suspension cell culture process to manufacture recombinant adenoviral vectors for gene therapy.

Cytotechnology

G Schoofs, T J Monica, J Ayala, J Horwitz, T Montgomery, G Roth, F J Castillo

Affiliations

  1. Fermentation and Cell Culture Development, Biotechnology R&D (CMC), Berlex Biosciences, 15409 San Pablo Avenue, Richmond, CA, 94804, U.S.A.

PMID: 19003410 PMCID: PMC3449833 DOI: 10.1023/A:1008021428969

Abstract

We have developed an efficient, reproducible, and scaleable cell culture process for a recombinant adenoviral vector expressing therapeutic transgenes for clinical trials. HEK 293 cells - which support the propagation of E1 deficient adenovirus - were first adapted to serum free media and suspension growth. Subsequent studies focused on the infection, virus production and harvest from suspension culture bioreactors. Future studies are planned to address the kinetics of adenovirus production in HEK 293 as well as in other cell lines.

References

  1. Methods Enzymol. 1979;58:425-35 - PubMed
  2. Cytotechnology. 1994;15(1-3):145-55 - PubMed
  3. Hum Gene Ther. 1997 Apr 10;8(6):775-800 - PubMed
  4. Biotechnol Bioeng. 1996 Sep 20;51(6):613-23 - PubMed
  5. Cytotechnology. 1992;8(3):231-6 - PubMed
  6. Methods Mol Biol. 1991;7:109-28 - PubMed
  7. Hum Gene Ther. 1997 Mar 1;8(4):453-65 - PubMed
  8. Science. 1995 Oct 20;270(5235):404-10 - PubMed

Publication Types